# Three Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Leg Syndrome

> **NCT00136045** · PHASE3 · COMPLETED · sponsor: **UCB Pharma** · enrollment: 549 (actual)

## Conditions studied

- Restless Legs Syndrome

## Interventions

- **DRUG:** Rotigotine

## Key facts

- **NCT ID:** NCT00136045
- **Lead sponsor:** UCB Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-05
- **Primary completion:** 2006-08
- **Final completion:** 2006-08
- **Target enrollment:** 549 (ACTUAL)
- **Last updated:** 2014-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00136045

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00136045, "Three Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Leg Syndrome". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00136045. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*